Press releases

• September 28, 2022 - Regulatory press releaseLecanemab phase 3 Clarity AD study in early Alzheimer’s disease meets primary and all key secondary endpoints with high statistical significance
• August 5, 2022 - Other press releaseLatest data on lecanemab presented at Alzheimer’s Association International Conference (AAIC)
• July 26, 2022 - Other press releaseLatest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC)

Archive

Calendar

• October 20, 2022Interim report January – September 2022
• February 3, 2023Full Year Report January – December 2022

Read more

Interim report Q2 2022

BioArctic AB published the company’s second quarter report for April – June 2022 on Tuesday, July 12, 2022, at 08:00 a.m. CET.

• Report
• Presentation
• Press release
• Webcast

Read the report

Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Read more

Parkinson’s disease

The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.

Read more

Neurodegenerative disorders

BioArctic is committed to help people with neurodegenerative disorders

Read more